

CURRICULUM VITAE

Angeli Landeros-Weisenberger, MD

Version Date: 10/13/2025

Contact Information:

Address 350 George St.
Ste A320
New Haven, CT 06511
Phone: 1 (203) 737-4809
Email: angeli.landeros@yale.edu

School: Yale School of Medicine

Education:

xxxx - 01/1999 MD, Facultad Mexicana de Medicina La Salle University, Mexico City, D.F., Mexico

Career/Academic Appointments:

02/2006 Psychiatry, Hospital Espanol de Mexico, UNAM, Mexico City, D.F., Mexico
07/2006 - 06/2009 Postdoctoral Fellow, Child Study Center, Yale School of Medicine, New Haven, CT
07/2009 - 07/2012 Postdoctoral Associate, Child Study Center, Yale School of Medicine, New Haven, CT
07/2009 Postdoctoral Research Fellow, Yale Child Study Center, Yale University, New Haven, CT
06/2012 Postdoctoral Associate, Yale Child Study Center, Yale University, New Haven, CT
08/2012 - 06/2014 Associate Research Scientist, Child Study Center, Yale School of Medicine, New Haven, CT
07/2014 - 06/2015 Assistant Clinical Professor, Child Study Center, Yale School of Medicine, New Haven, CT
08/2015 - 06/2026 Associate Research Scientist, Child Study Center, Yale School of Medicine, New Haven, CT

Administrative Positions:

2017 - 2020 Member A&P and Mentoring Committee for ARS , Yale Child Study Center, Yale University, New Haven, CT
2020 - 2023 ARS Representative, Faculty Advisory Committee for the Dean, Yale School of Medicine, New Haven, CT
2020 - Present Chair of the A&P and Mentoring ARS Committee, Yale Child Study Center, Yale University, New Haven, CT

2022 - Present	Co-chair Pediatric Protocol Review Committee, Yale Center for Clinical Investigation (YCCI), Yale School of Medicine, New Haven, CT
2023 - Present	Member of the FAC executive committee, Yale School of Medicine, Yale University, New Haven, CT
2023 - Present	Member of DEI subcommittee for FAC , Yale School of Medicine, Yale University, New Haven, CT
2023 - 2024	Member Human Investigation Committee 4-B, Yale HRPP, Yale University, New Haven, CT
2024 - Present	Faculty At Large, Educational Policy and Curriculum Committee Members, Yale School of Medicine, New Haven, CT

Professional Honors & Recognition:

International/National/Regional

2020 Women Physician Inspiration Award Honoree 2020, American Medical Association

Other

2006 - 2008 ACNP Young Investigator Travel Award,, American College of Neuropsychopharmacology

Grants/Clinical Trials History:

Current Clinical Trials

Agencies: University of Iowa, National Institute of Mental Health (NIMH), Klingenstein Third Generation Foundation
I.D.#: 0407026910
Title: Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)
P.I.: Hilary Blumberg
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 08/17/2004 - ongoing

Agencies: National Institute of Mental Health (NIMH), Stanford University
I.D.#: 1104008337
Title: Integrated Approach to the Neurobiology of Autism Spectrum Disorders and Tourette Syndrome
P.I.: Flora Vaccarino
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/07/2011 - ongoing

Agencies: Simons Foundation
 I.D.#: 2000021581
 Title: Treatment Study for Children with Autism Spectrum Disorder
 P.I.: Denis Sukhodolsky
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 10/25/2017 - ongoing

Agencies: Yale University School of Medicine, National Center for Advancing Translational Sciences (NCATS), Nancy Taylor Foundation for Chronic Diseases, Inc.
 I.D.#: 2000021811
 Title: PET and MRI in OCD and/or Tic disorders
 P.I.: Christopher Pittenger
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: 0.0000
 Project period: 11/13/2017 - ongoing

Agencies: National Institute of Mental Health (NIMH)
 I.D.#: 2000026094
 Title: Longitudinal Study of Adulthood Outcome in Children with Tourette Syndrome
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 07/26/2019 - ongoing

Agencies: Neurocrine Biosciences, Inc.
 I.D.#: 2000034993
 Title: Valbenazine for Trichotillomania in Adults
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/31/2023 - ongoing

Agencies: Emalex Biosciences, Inc.
 I.D.#: 2000035226
 Title: The D1AMOND long-term safety extension study of ecopipam tablets in children, adolescents, and adults with Tourette's Disorder
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A

Total costs: -
Project period: 03/08/2024 - ongoing

Past Clinical Trials

Agencies: National Alliance for Research on Schizophrenia and Depression
I.D.#: 1004006623
Title: N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/07/2010 - 02/15/2018

Agencies: American Academy of Child and Adolescent Psychiatry
I.D.#: 1004006637
Title: Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the treatment of Tourette Syndrome
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 06/07/2010 - 03/27/2017

Agencies: National Institute of Mental Health (NIMH)
I.D.#: 1005006740
Title: Longitudinal MRI Study of Adulthood Outcome in Children with Tourette Syndrome
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/15/2010 - 07/10/2018

Agencies: National Institutes of Health (NIH), Brain and Behavior Research Foundation
I.D.#: 1110009142
Title: Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD) (IBBS)
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 11/28/2011 - 12/03/2018

Agencies: Rembrandt Foundation
I.D.#: 1201009539

Title: Open-Trial of EPI-743 for the Treatment of Adults with Tourette Syndrome
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 03/20/2012 - 01/08/2015

Agencies: Robert Leet and Clara Guthrie Patterson Trust
I.D.#: 1310012947
Title: Ketamine Infusion for Social Anxiety Disorder
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 01/03/2014 - 09/07/2017

Agencies: Tourette Syndrome Association, Inc.
I.D.#: 1403013669
Title: FAAH Inhibitor Trial for Adults With Tourette Syndrome
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 04/28/2014 - 03/16/2017

Agencies: American Academy of Child and Adolescent Psychiatry, Thrasher Research Fund
I.D.#: 1506016041
Title: Ketamine Infusion for Adolescent Depression
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/24/2015 - 09/09/2019

Agencies: Biohaven Pharmaceuticals Inc.
I.D.#: 1605017768
Title: Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
P.I.: Michael Bloch
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/12/2016 - 05/23/2018

Agencies: Yale University School of Medicine, Therapix Biosciences Ltd.

I.D.#: 1610018525
 Title: Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 11/07/2016 - 09/07/2018

Agencies: Yale University School of Medicine
 I.D.#: 2000020431
 Title: Evaluation of glutamate levels in adolescent mood disorders
 P.I.: Irina Esterlis
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/12/2017 - 03/09/2020

Agencies: Neurocrine Biosciences, Inc.
 I.D.#: 2000022093
 Title: Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/08/2018 - 01/10/2019

Agencies: Janssen Research & Development, LLC
 I.D.#: 2000022059
 Title: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 02/20/2018 - 03/30/2023

Agencies: Neurocrine Biosciences, Inc.
 I.D.#: 2000022997
 Title: Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 08/31/2018 - 10/18/2019

Agencies: Massachusetts General Hospital
 I.D.#: 2000024167
 Title: AFQ056 for Language Learning in Children With FXS
 P.I.: Roger J. Jou
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 01/29/2019 - 05/06/2021

Agencies: American Academy of Child and Adolescent Psychiatry, Klingenstein Third Generation Foundation
 I.D.#: 2000023857
 Title: Ketamine for severe adolescent depression: intermediate-term safety and efficacy
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 04/29/2019 - 08/10/2022

Agencies: Biohaven Pharmaceuticals Inc.
 I.D.#: 2000024951
 Title: Randomized Trial of Adult Subjects With Generalized Anxiety Disorder
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 05/01/2019 - 11/25/2019

Agencies: Emalex Biosciences, Inc.
 I.D.#: 2000026173
 Title: Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents (D1AMOND)
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 01/07/2020 - 12/17/2021

Agencies: Duke Clinical Research Institute
 I.D.#: 2000026791
 Title: Long-term Antipsychotic Pediatric Safety Trial (LAPS)
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/02/2020 - 05/07/2021

Agencies: Emalex Biosciences, Inc.
 I.D.#: 2000027699
 Title: Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension (D1AMOND)
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 03/02/2021 - 12/12/2022

Agencies: Bionomics Limited
 I.D.#: 2000032550
 Title: A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL)
 P.I.: Michael Bloch
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 06/24/2022 - 12/07/2022

Pending Clinical Trials

Agencies: Yale University School of Medicine, Nancy Taylor Foundation for Chronic Diseases, Inc.
 I.D.#: 2000025114
 Title: Imaging Glutamatergic Markers in Adolescents
 P.I.: Irina Esterlis
 Role: Sub-Investigator
 Percent effort: N/A
 Total costs: -
 Project period: 08/13/2019 - ongoing

Agencies: SciSparc Ltd
 I.D.#: 2000033527

Title: A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults with Tourette Syndrome

P.I.: Michael Bloch

Role: Sub-Investigator

Percent effort: N/A

Total costs: -

Project period: 06/12/2023 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. "Tourette Syndrome". CoPedia: The 3rd World Congress on Controversies in Pediatrics, Tourette Syndrome, Barcelona, CT, January 2015. (Lecture)
2. "Cuando vivir se convierte en una carga". Jornanda sobre Suicidio, Centro Hospitalario Padre Menini Santander, CB Spain, April 2022. (Lecture)
3. "Manejo del Trastorno Depresivo Mayor Resistente en Adolescentes". Curso para residentes de psiquiatria, Hospital Espanol de Mexico Sala 9 de Psiquiatria CDMX, Mexico, August 2022. (Lecture)

Professional Service:

Peer Review Groups/Grant Study Sections

2022 - Present Chair, Yale Child A&P ARS Committee, We review applications for faculty looking to move up the research track

Advisory Boards

2019 - 2023 Ad-hoc Member, Faculty Advisory Committee to the Dean, Yale School of Medicine

Journal Services

Reviewer

2012 - Present Reviewer, Psychiatry Research

2015 - Present Reviewer, Journal of Pediatric Biochemistry

2018 - Present Reviewer, Brain Sciences

2019 - Present Reviewer, International Journal of Environmental Research and Public Health

2019 - Present Reviewer, Nutrients

2019 - Present Reviewer, Journal of Clinical Medicine

2019 - Present Reviewer, Children

2019 - Present Reviewer, Journal of Clinical Medicine

2022 - Present Reviewer, Expert Opinion On Pharmacotherapy

Yale University / Hospital System

Medical School

2020 - 2023 Board Member, FAC for the Dean Yale School of Medicine, Elected member of the Dean's Faculty Advisory Committee representing Associate Research Scientists

Department

2017 - Present Chair, Yale Child Study Center ARS Mentorship, Yale Child Study Center ARS Appointments & Promotions Committee

2018 - Present Ad-hoc Member, YCSC Faculty Compensation Guidelines Committee, YCSC Faculty Compensation Committee

Hospital

2005 - 2006 Vice President, Grupo de Residentes del Hospital Espanol, Vice-president to the Medical Residency Committee at the Hospital Espanol de Mexico: organizing committee for resident's academic summit within the Hospital.

Public Service / Media Presence

Public Service

2000 - 2001 Physician, SSA, Social Service requirement for medical training. Did one year as a General medical doctor in the town of Otatitlan, Veracruz in Mexico, stationed in a rural clinic where I would provide medical attention (management of emergencies, regular check-ups, follow up visits for chronic diseases, community and school engagement and education; as well implementation of governmental epidemiological programs and surveys.

Bibliography:

Peer-Reviewed Original Research

1. Bloch MH, **Landeros-Weisenberger A** , Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. *Molecular Psychiatry* 2006, 11: 622-632. [PMID: 16585942](#) , [DOI: 10.1038/sj.mp.4001823](#) .
2. Bloch M, **Landeros-Weisenberger A** , Kelmendi B, Coric V, Bracken M, Leckman J. Erratum: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. *Molecular Psychiatry* 2006, 11: 795-795. [DOI: 10.1038/sj.mp.4001859](#) .
3. **Landeros-Weisenberger A** . Child and Adolescent Psychiatry: The Essentials Keith Cheng Kathleen M. Myers Child and Adolescent Psychiatry: The Essentials 2005 Lippincott Williams & Wilkins Philadelphia 416\$74.95 (hardcover). *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2006, 45: 1146. [DOI: 10.1097/01.chi.0000235081.55532.a5](#) .
4. Bloch MH, **Landeros-Weisenberger A** , Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. *Biological Psychiatry* 2007, 62: 839-846. [PMID: 17727824](#) , [DOI: 10.1016/j.biopsych.2007.05.019](#) .

5. Bloch M, **Landeros-Weisenberger A**, Dombrowski P, Nudel J, Pittenger C, Leckman J, Kelmendi B, Wegner R, Coric V. Response to Chamberlain et al. Re: Systematic Review: Pharmacological and Behavioral Treatments for Trichotillomania. *Biological Psychiatry* 2008, 63: e34-e35. [DOI: 10.1016/j.biopsych.2008.01.022](#) .
6. Bloch MH, **Landeros-Weisenberger A**, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: Systematic review. *American Journal Of Medical Genetics Part B Neuropsychiatric Genetics* 2008, 147B: 850-858. [PMID: 18186076](#) , [DOI: 10.1002/ajmg.b.30699](#) .
7. Leslie DL, Kozma L, Martin A, Landeros A, Katsoyich L, King RA, Leckman JF. Neuropsychiatric Disorders Associated With Streptococcal Infection: A Case-Control Study Among Privately Insured Children. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2008, 47: 1166-1172. [PMID: 18724258](#) , [PMCID: PMC2783578](#) , [DOI: 10.1097/chi.0b013e3181825a3d](#) .
8. Bloch MH, **Landeros-Weisenberger A**, Rosario MC, Pittenger C, Leckman JF. Meta-Analysis of the Symptom Structure of Obsessive-Compulsive Disorder. *American Journal Of Psychiatry* 2008, 165: 1532-1542. [PMID: 18923068](#) , [PMCID: PMC3972003](#) , [DOI: 10.1176/appi.ajp.2008.08020320](#) .
9. Bloch MH, McGuire J, **Landeros-Weisenberger A**, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. *Molecular Psychiatry* 2009, 15: 850-855. [PMID: 19468281](#) , [PMCID: PMC2888928](#) , [DOI: 10.1038/mp.2009.50](#) .
10. **Landeros-Weisenberger A**, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. *Journal Of Affective Disorders* 2009, 121: 175-179. [PMID: 19577308](#) , [PMCID: PMC3974618](#) , [DOI: 10.1016/j.jad.2009.06.010](#) .
11. Bloch MH, Panza KE, **Landeros-Weisenberger A**, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2009, 48: 884-893. [PMID: 19625978](#) , [PMCID: PMC3943246](#) , [DOI: 10.1097/chi.0b013e3181b26e9f](#) .
12. Bloch MH, Craiglow BG, **Landeros-Weisenberger A**, Dombrowski PA, Panza KE, Peterson BS, Leckman JF. Predictors of Early Adult Outcomes in Pediatric-Onset Obsessive-Compulsive Disorder. 2009, 124: 1085-1093. [PMID: 19786445](#) , [PMCID: PMC3974608](#) , [DOI: 10.1542/peds.2009-0015](#) .
13. Lin H, Williams KA, Katsoyich L, Findley DB, Grantz H, Lombroso PJ, King RA, Bessen DE, Johnson D, Kaplan EL, **Landeros-Weisenberger A**, Zhang H, Leckman JF. Streptococcal Upper Respiratory Tract Infections and Psychosocial Stress Predict Future Tic and Obsessive-Compulsive Symptom Severity in Children and Adolescents with Tourette Syndrome and Obsessive-Compulsive Disorder. *Biological Psychiatry* 2009, 67: 684-691. [PMID: 19833320](#) , [PMCID: PMC2843763](#) , [DOI: 10.1016/j.biopsych.2009.08.020](#) .
14. Jacob S, **Landeros-Weisenberger A**, Leckman JF. Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and genetics. *Autism Research* 2009, 2: 293-311. [PMID: 20029829](#) , [PMCID: PMC3974607](#) , [DOI: 10.1002/aur.108](#) .
15. Palermo SD, Bloch MH, Craiglow B, **Landeros-Weisenberger A**, Dombrowski PA, Panza K, Smith ME, Peterson BS, Leckman JF. Predictors of early adulthood quality of life in children with obsessive-compulsive disorder. *Social Psychiatry And Psychiatric Epidemiology* 2010, 46: 291-297. [PMID: 20191262](#) , [PMCID: PMC3645906](#) , [DOI: 10.1007/s00127-010-0194-2](#) .
16. Motlagh MG, Sukhodolsky DG, **Landeros-Weisenberger A**, Katsoyich L, Thompson N, Scahill L, King RA, Peterson BS, Schultz RT, Leckman JF. Adverse Effects of Heavy Prenatal Maternal Smoking on

- Attentional Control in Children With ADHD. *Journal Of Attention Disorders* 2010, 15: 593-603. [PMID: 20616372](#) , [PMCID: PMC3974616](#) , [DOI: 10.1177/1087054710374576](#) .
17. Sukhodolsky DG, **Landeros-Weisenberger A** , Scahill L, Leckman JF, Schultz RT. Neuropsychological Functioning in Children With Tourette Syndrome With and Without Attention-Deficit/Hyperactivity Disorder. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2010, 49: 1155-1164.e1. [PMID: 20970703](#) , [PMCID: PMC2965169](#) , [DOI: 10.1016/j.jaac.2010.08.008](#) .
 18. Bloch MH, Sukhodolsky DG, Dombrowski PA, Panza KE, Craiglow BG, **Landeros-Weisenberger A** , Leckman JF, Peterson BS, Schultz RT. Poor fine-motor and visuospatial skills predict persistence of pediatric-onset obsessive-compulsive disorder into adulthood. *Journal Of Child Psychology And Psychiatry* 2011, 52: 974-983. [PMID: 21244423](#) , [PMCID: PMC3625937](#) , [DOI: 10.1111/j.1469-7610.2010.02366.x](#) .
 19. Jacob S, **Landeros-Weisenberger A** , Leckman J. Interface Between Autism Spectrum Disorders and Obsessive-Compulsive Behaviors: A Genetic and Developmental Perspective. 2011, 285-303. [DOI: 10.1093/med/9780195371826.003.0020](#) .
 20. Chalita PJ, Palacios L, Cortes JF, **Landeros-Weisenberger A** , Panza KE, Bloch MH. Relationship of Dropout and Psychopathology in a High School Sample in Mexico. *Frontiers In Psychiatry* 2012, 3: 20. [PMID: 22419912](#) , [PMCID: PMC3300101](#) , [DOI: 10.3389/fpsy.2012.00020](#) .
 21. Qawasmi A, **Landeros-Weisenberger A** , Leckman JF, Bloch MH. Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition. 2012, 129: 1141-1149. [PMID: 22641753](#) , [PMCID: PMC3362904](#) , [DOI: 10.1542/peds.2011-2127](#) .
 22. Bloch MH, Wasylink S, **Landeros-Weisenberger A** , Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. *Biological Psychiatry* 2012, 72: 964-970. [PMID: 22784486](#) , [PMCID: PMC3667652](#) , [DOI: 10.1016/j.biopsych.2012.05.028](#) .
 23. Qawasmi A, **Landeros-Weisenberger A** , Bloch MH. Meta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity. 2013, 131: e262-e272. [PMID: 23248232](#) , [PMCID: PMC3529943](#) , [DOI: 10.1542/peds.2012-0517](#) .
 24. Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, **Landeros-Weisenberger A** , Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG-TERM OUTCOME IN ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER. *Depression And Anxiety* 2013, 30: 716-722. [PMID: 23532944](#) , [PMCID: PMC3932438](#) , [DOI: 10.1002/da.22103](#) .
 25. King R, **Landeros-Weisenberger A** . Comprehensive Assessment Strategies. 2013, 402-410. [DOI: 10.1093/med/9780199796267.003.0018](#) .
 26. Motlagh MG, Smith ME, **Landeros-Weisenberger A** , Kobets AJ, King RA, Miravite J, de Lotbinière AC, Alterman RL, Mogilner AY, Pourfar MH, Okun MS, Leckman JF. Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years. *Tremor And Other Hyperkinetic Movements* 2013, 3: tre-03-170-4428-1. [PMID: 24255802](#) , [PMCID: PMC3822402](#) , [DOI: 10.5334/tohm.126](#) .
 27. Bloch MH, Bartley CA, Zipperer L, Jakubovski E, **Landeros-Weisenberger A** , Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. *Molecular Psychiatry* 2014, 19: 1025-1030. [PMID: 24912494](#) , [PMCID: PMC4169729](#) , [DOI: 10.1038/mp.2014.50](#) .
 28. **Landeros-Weisenberger A** , Mantovani A, Motlagh MG, de Alvarenga PG, Katsoyich L, Leckman JF, Lisanby SH. Randomized Sham Controlled Double-blind Trial of Repetitive Transcranial Magnetic

- Stimulation for Adults With Severe Tourette Syndrome. *Brain Stimulation* 2014, 8: 574-581. [PMID: 25912296](#) , [PMCID: PMC4454615](#) , [DOI: 10.1016/j.brs.2014.11.015](#) .
29. Bloch M, **Landeros-Weisenberger A** , Rosario M, Pittenger C, Leckman J. Meta-Analysis of the Symptom Structure of Obsessive-Compulsive Disorder. *FOCUS The Journal Of Lifelong Learning In Psychiatry* 2015, 13: 232-243. [DOI: 10.1176/appi.focus.130209](#) .
 30. Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, **Landeros-Weisenberger A** , Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. *Journal Of Child And Adolescent Psychopharmacology* 2016, 26: 327-334. [PMID: 27027204](#) , [PMCID: PMC6445198](#) , [DOI: 10.1089/cap.2015.0109](#) .
 31. Vitulano L, Grantz H, **Landeros-Weisenberger A** , Katsoyich L, Artukoglu B, Aktan S, Wang M, Geoffrion C, Vitulano M, Wexler B. 6.62 VALUE OF PARENT AND CLINICIAN RATINGS AND GENDER DIFFERENCES IN THE PREDICTABILITY OF RESPONSES TO INTEGRATED COMPUTER-PRESENTED AND PHYSICAL BRAIN-TRAINING EXERCISES. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2016, 55: s224. [DOI: 10.1016/j.jaac.2016.09.381](#) .
 32. Johnston JAY, Wang F, Liu J, Blond BN, Wallace A, Liu J, Spencer L, Cox Lippard ET, Purves KL, **Landeros-Weisenberger A** , Hermes E, Pittman B, Zhang S, King R, Martin A, Oquendo MA, Blumberg HP. Multimodal Neuroimaging of Frontolimbic Structure and Function Associated With Suicide Attempts in Adolescents and Young Adults With Bipolar Disorder. *American Journal Of Psychiatry* 2017, 174: 667-675. [PMID: 28135845](#) , [PMCID: PMC5939580](#) , [DOI: 10.1176/appi.ajp.2016.15050652](#) .
 33. Taylor JH, **Landeros-Weisenberger A** , Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. *Neuropsychopharmacology* 2017, 43: 325-333. [PMID: 28849779](#) , [PMCID: PMC5729569](#) , [DOI: 10.1038/npp.2017.194](#) .
 34. Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, **Landeros-Weisenberger A** , Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. *Journal Of Child And Adolescent Psychopharmacology* 2019, 30: 32-37. [PMID: 31800306](#) , [PMCID: PMC7133418](#) , [DOI: 10.1089/cap.2019.0041](#) .
 35. Szejko N, Lombroso A, Bloch MH, **Landeros-Weisenberger A** , Leckman JF. Refractory Gilles de la Tourette Syndrome—Many Pieces That Define the Puzzle. *Frontiers In Neurology* 2020, 11: 589511. [PMID: 33391155](#) , [PMCID: PMC7775596](#) , [DOI: 10.3389/fneur.2020.589511](#) .
 36. Londono Tobon A, Flores JM, Taylor JH, Johnson I, **Landeros-Weisenberger A** , Aboiralor O, Avila-Quintero VJ, Bloch MH. Racial Implicit Associations in Psychiatric Diagnosis, Treatment, and Compliance Expectations. *Academic Psychiatry* 2021, 45: 23-33. [PMID: 33438155](#) , [PMCID: PMC7933096](#) , [DOI: 10.1007/s40596-020-01370-2](#) .
 37. Dwyer JB, **Landeros-Weisenberger A** , Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. *American Journal Of Psychiatry* 2021, 178: 352-362. [PMID: 33653121](#) , [DOI: 10.1176/appi.ajp.2020.20010018](#) .
 38. Londono Tobon A, Flores JM, Taylor JH, Johnson I, **Landeros-Weisenberger A** , Aboiralor O, Avila-Quintero VJ, Bloch MH. Correction to: Racial Implicit Associations in Psychiatric Diagnosis, Treatment, and Compliance Expectations. *Academic Psychiatry* 2021, 45: 533-534. [PMID: 33821450](#) , [DOI: 10.1007/s40596-021-01435-w](#) .

39. Bloch MH, **Landeros-Weisenberger A**, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ^9 -Tetrahydrocannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome. *Journal Of Neuropsychiatry* 2021, 33: 328-336. [PMID: 34340527](#) , [DOI: 10.1176/appi.neuropsych.19080178](#) .
40. Farhat LC, Vattimo EFQ, Ramakrishnan D, Levine JLS, Johnson JA, Artukoglu BB, **Landeros-Weisenberger A** , Asbahr FR, Cepeda SL, Comer JS, Fatori D, Franklin ME, Freeman JB, Geller DA, Grant PJ, Goodman WK, Heyman I, Ivarsson T, Lenhard F, Lewin AB, Li F, Merlo LJ, Mohsenabadi H, Peris TS, Piacentini J, Rosa-Alcázar AI, Rosa-Alcázar À, Rozenman M, Sapyta JJ, Serlachius E, Shabani MJ, Shavitt RG, Small BJ, Skarphedinsson G, Swedo SE, Thomsen PH, Turner C, Weidle B, Miguel EC, Storch EA, Mataix-Cols D, Bloch MH. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2021, 61: 495-507. [PMID: 34597773](#) , [DOI: 10.1016/j.jaac.2021.05.027](#) .
41. Behling E, Farhat LC, **Landeros-Weisenberger A** , Bloch MH. Meta-Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. *Movement Disorders* 2022, 37: 684-693. [PMID: 35191552](#) , [DOI: 10.1002/mds.28957](#) .
42. King R, **Landeros-Weisenberger A** . Comprehensive Assessment Strategies. 2022, 335-342. [DOI: 10.1093/med/9780197543214.003.0020](#) .
43. Dwyer J, **Landeros-Weisenberger A** , Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. *FOCUS The Journal Of Lifelong Learning In Psychiatry* 2022, 20: 241-251. [PMID: 37153136](#) , [PMCID: PMC10153503](#) , [DOI: 10.1176/appi.focus.22020004](#) .
44. Brady M, Mariani J, Koca Y, Szekely A, King R, Bloch M, **Landeros-Weisenberger A** , Leckman J, Vaccarino F. Mispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids. *Molecular Psychiatry* 2022, 27: 5007-5019. [PMID: 36447010](#) , [PMCID: PMC9949887](#) , [DOI: 10.1038/s41380-022-01880-5](#) .
45. Farhat L, Behling E, **Landeros-Weisenberger A** , Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. *The Lancet Child & Adolescent Health* 2022, 7: 112-126. [PMID: 36528030](#) , [DOI: 10.1016/s2352-4642\(22\)00316-9](#) .
46. Brady M, Mariani J, Koca Y, Szekely A, King R, Bloch M, **Landeros-Weisenberger A** , Leckman J, Vaccarino F. Characterization of human basal ganglia organoids. *Molecular Psychiatry* 2022, 27: 4823-4823. [PMID: 36536052](#) , [DOI: 10.1038/s41380-022-01914-y](#) .
47. Ramakrishnan D, Farhat L, Vattimo E, Levine J, Johnson J, Artukoglu B, **Landeros-Weisenberger A** , Zangen A, Pelissolo A, de B Pereira C, Rück C, Costa D, Mataix-Cols D, Shannahoff-Khalsa D, Tolin D, Zarean E, Meyer E, Hawken E, Storch E, Andersson E, Miguel E, Maina G, Leckman J, Sarris J, March J, Diniz J, Kobak K, Mallet L, Vulink N, Amiaz R, Fernandes R, Shavitt R, Wilhelm S, Golshan S, Tezenas du Montcel S, Erzegovesi S, Baruah U, Greenberg W, Kobayashi Y, Bloch M. An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. *Journal Of Psychiatric Research* 2024, 173: 387-397. [PMID: 38598877](#) , [DOI: 10.1016/j.jpsychires.2024.03.044](#) .

48. Malison K, Avila-Quintero V, Al-Mateen C, Flores J, **Landeros-Weisenberger A** , Njoroge W, Novins D, Robles-Ramamurthy B, Taylor J, Bloch M, Tobón A. Racial Implicit Associations in Child Psychiatry. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2024, 64: 734-744. [PMID: 38823476](#) , [DOI: 10.1016/j.jaac.2024.04.013](#) .
49. Farhat L, Behling E, **Landeros-Weisenberger A** , de Barros P, Polanczyk G, Cortese S, Bloch M. Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. *Journal Of Child And Adolescent Psychopharmacology* 2024, 34: 373-382. [PMID: 39320340](#) , [PMCID: PMC11807863](#) , [DOI: 10.1089/cap.2024.0049](#) .
50. Macul Ferreira de Barros P, Farhat L, Behling E, Nasir M, **Landeros-Weisenberger A** , Bloch M. Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette’s Disorder Medications. *Journal Of The American Academy Of Child & Adolescent Psychiatry* 2024, 64: 577-592. [PMID: 39505141](#) , [DOI: 10.1016/j.jaac.2024.10.011](#) .
51. Avila-Quintero V, Malison K, Wilkerson M, Flores J, Taylor J, **Landeros-Weisenberger A** , Bloch M, Tobón A. Associations between childhood interactions with people of Black race/ethnicity and racial implicit association tasks in psychiatric providers in the United States – a cross-sectional study. *Child And Adolescent Mental Health* 2025, 30: 256-264. [PMID: 40574470](#) , [DOI: 10.1111/camh.70001](#) .